InsiderSignal.AI

InsiderSignal.ai

ELVN - Enliven Therapeutics, Inc.

Insider Sale by Collins Helen Louise (Chief Medical Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Collins Helen Louise, serving as Chief Medical Officer at Enliven Therapeutics, Inc. (ELVN), sold 5,000 shares at $27.76 per share, for a total transaction value of $138,800.00. Following this transaction, Collins Helen Louise now holds 25,000 shares of ELVN.

This sale represents a 17.00% decrease in Collins Helen Louise's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 19, 2026, 2 days after the trade was made.

Enliven Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Collins Helen Louise

Chief Medical Officer

Helen Louise Collins, MD is the Chief Medical Officer at Enliven Therapeutics, Inc. (NASDAQ: ELVN), where she has recently engaged in insider trading activities, including selling 45,000 shares on February 17, 2026[[5]](https://www.tradingview.com/news/tradingview:083f7af17e090:0-enliven-therapeutics-cmo-sells-45-000-shares/)[[8]](https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-da1465233091.html) and exercising options in related transactions[[8]](https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-da1465233091.html). She holds approximately 171,000 shares valued at around $5.03 million as of recent reports[[7]](https://stockcircle.com/insider-trades/person/collins-helen-louise). Dr. Collins brings over 25 years of experience in oncology and hematology to her role. Prior to Enliven, she served as Chief Medical Officer and Executive Vice President at Five Prime Therapeutics until its acquisition by Amgen in April 2021[[1]](https://www.enliventherapeutics.com/about/)[[2]](https://kuraoncology.com/leadership/helen-collins-m-d/)[[3]](https://investors.iobiotech.com/governance/board-of-directors/person-details/default.aspx?ItemId=4c2e6209-8cc0-41d4-9c52-288a85de50d5). She previously held senior positions at Gilead Sciences as Program and Clinical Lead for BTK and BET inhibitor programs, and at Amgen as Global Lead for Oncology Biosimilars[[1]](https://www.enliventherapeutics.com/about/)[[2]](https://kuraoncology.com/leadership/helen-collins-m-d/)[[3]](https://investors.iobiotech.com/governance/board-of-directors/person-details/default.aspx?ItemId=4c2e6209-8cc0-41d4-9c52-288a85de50d5). Earlier, she practiced as a medical oncologist and hematologist for 12 years at Redwood Regional Medical Group[[1]](https://www.enliventherapeutics.com/about/)[[2]](https://kuraoncology.com/leadership/helen-collins-m-d/)[[3]](https://investors.iobiotech.com/governance/board-of-directors/person-details/default.aspx?ItemId=4c2e6209-8cc0-41d4-9c52-288a85de50d5). Dr. Collins serves on the boards of directors of Kura Oncology (since July 2021)[[1]](https://www.enliventherapeutics.com/about/)[[2]](https://kuraoncology.com/leadership/helen-collins-m-d/) and IO Biotech (since November 2023)[[3]](https://investors.iobiotech.com/governance/board-of-directors/person-details/default.aspx?ItemId=4c2e6209-8cc0-41d4-9c52-288a85de50d5). She earned her M.D. from Johns Hopkins University School of Medicine, completed residency at Johns Hopkins Hospital and fellowship at Stanford University School of Medicine in gastrointestinal cancer, and holds an A.B. in Chemistry from Bryn Mawr College; she is board-certified in oncology[[1]](https://www.enliventherapeutics.com/about/)[[2]](https://kuraoncology.com/leadership/helen-collins-m-d/)[[3]](https://investors.iobiotech.com/governance/board-of-directors/person-details/default.aspx?ItemId=4c2e6209-8cc0-41d4-9c52-288a85de50d5).

View full insider profile →

Trade Price

$27.76

Quantity

5,000

Total Value

$138,800.00

Shares Owned

25,000

Trade Date

Tuesday, March 17, 2026

6 days ago

SEC Filing Date

Thursday, March 19, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Enliven Therapeutics, Inc.

Company Overview

No company information available
View news mentioning ELVN

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4922154

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime